WO2010023670A3 - Procédés permettant de fixer par covalence un polymère à un résidu de méthionine dans des protéines et des peptides - Google Patents

Procédés permettant de fixer par covalence un polymère à un résidu de méthionine dans des protéines et des peptides Download PDF

Info

Publication number
WO2010023670A3
WO2010023670A3 PCT/IL2009/000832 IL2009000832W WO2010023670A3 WO 2010023670 A3 WO2010023670 A3 WO 2010023670A3 IL 2009000832 W IL2009000832 W IL 2009000832W WO 2010023670 A3 WO2010023670 A3 WO 2010023670A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
proteins
polymer
methods
methionine residue
Prior art date
Application number
PCT/IL2009/000832
Other languages
English (en)
Other versions
WO2010023670A2 (fr
Inventor
Joel M. Van Gelder
Andrei Serban
Susanna Tchilibon
Daphna Miron
Original Assignee
Insight Biopharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insight Biopharmaceuticals Ltd. filed Critical Insight Biopharmaceuticals Ltd.
Priority to US13/060,439 priority Critical patent/US20110150820A1/en
Publication of WO2010023670A2 publication Critical patent/WO2010023670A2/fr
Publication of WO2010023670A3 publication Critical patent/WO2010023670A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des conjugués de polypeptides et une fraction polymère telle que le PEG fixée par covalence à l'atome de soufre d'une chaîne latérale de méthionine. L'invention concerne également des procédés de préparation de ces conjugués, y compris les composés intermédiaires et les réactifs utilisés par conséquent. L'invention concerne en outre les utilisations thérapeutiques de ces conjugués.
PCT/IL2009/000832 2008-08-28 2009-08-27 Procédés permettant de fixer par covalence un polymère à un résidu de méthionine dans des protéines et des peptides WO2010023670A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/060,439 US20110150820A1 (en) 2008-08-28 2009-08-27 Methods for covalently attaching a polymer to a methionine residue in proteins and peptides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13633208P 2008-08-28 2008-08-28
US61/136,332 2008-08-28

Publications (2)

Publication Number Publication Date
WO2010023670A2 WO2010023670A2 (fr) 2010-03-04
WO2010023670A3 true WO2010023670A3 (fr) 2010-09-02

Family

ID=41567246

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2009/000832 WO2010023670A2 (fr) 2008-08-28 2009-08-27 Procédés permettant de fixer par covalence un polymère à un résidu de méthionine dans des protéines et des peptides

Country Status (2)

Country Link
US (1) US20110150820A1 (fr)
WO (1) WO2010023670A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081755A1 (es) * 2010-04-02 2012-10-17 Hanmi Holdings Co Ltd Formulacion de accion prolongada de la hormona estimuladora de los foliculos donde se usa un fragmento de inmunoglobulina, metodo de preparacion y metodo para tratar a un sujeto que sufre un trastorno reproductivo
US20140275420A1 (en) * 2011-08-22 2014-09-18 Carnegie Mellon University Atom transfer radical polymerization under biologically compatible conditions
EP2831090A4 (fr) * 2012-03-26 2015-11-11 Univ California Préparation de polypeptides, de peptides et de protéines fonctionnalisés par alkylation de groupes thioéther
US9718921B2 (en) 2013-02-26 2017-08-01 The Regents Of The University Of California Amphiphilic derivatives of thioether containing block copolypeptides
WO2016154120A1 (fr) 2015-03-20 2016-09-29 The Regents Of The University Of California Polypeptides, peptides et protéines fonctionnalisé(e)s par alkylation de groupes thioéther via des réactions d'ouverture de cycle
EP3124495A1 (fr) 2015-07-31 2017-02-01 Centre National de la Recherche Scientifique (C.N.R.S.) Dérivés de polypeptides de type élastine et leurs utilisations
US11732008B2 (en) 2016-04-27 2023-08-22 The Regents Of The University Of California Preparation of functional homocysteine residues in polypeptides and peptides
EP3652316A4 (fr) 2017-07-11 2021-04-07 Synthorx, Inc. Incorporation de nucléotides non naturels et procédés associés
TWI757528B (zh) 2017-08-03 2022-03-11 美商欣爍克斯公司 用於增生及感染性疾病治療之細胞激素結合物
CN111378026A (zh) * 2018-12-27 2020-07-07 天津键凯科技有限公司 一种制备结合位点可控的peg化生物分子的方法
BR112021014415A2 (pt) 2019-02-06 2021-09-21 Synthorx, Inc. Conjugados de il-2 e métodos de uso dos mesmos
CN114617957B (zh) * 2022-03-10 2024-01-16 中国人民解放军军事科学院军事医学研究院 羟乙基淀粉血红蛋白偶联物及其制备方法与应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ541124A (en) * 2002-12-26 2008-08-29 Mountain View Pharmaceuticals Polymer conjugates of interferon-beta with enhanced biological potency

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CARLSSON ET AL: "The selective S-alkylation of a methionine residue in an elapid venom cardiotoxin", INTERNATIONAL JOURNAL OF BIOCHEMISTRY, PERGAMON LNKD- DOI:10.1016/0020-711X(87)90172-8, vol. 19, no. 10, 1 January 1987 (1987-01-01), pages 915 - 921, XP023403021, ISSN: 0020-711X, [retrieved on 19870101] *
CZUPRYN M J ET AL: "STRUCTURE-FUNCTION RELATIONSHIPS IN HUMAN INTERLEUKIN-11: IDENTIFICATION OF REGIONS INVOLVED IN ACTIVITY BY CHEMICAL MODIFICATION AND SITE-DIRECTED MUTAGENESIS", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC, US LNKD- DOI:10.1074/JBC.270.2.978, vol. 270, no. 2, 13 January 1995 (1995-01-13), pages 978 - 985, XP001205296, ISSN: 0021-9258 *
KNUESLI C ET AL: "Polyethylene glycol (PEG) modification of granulocyte-macrophage colony stimulating factor (GM-CSF) enhances neutrophil priming activity but not colony stimulating activity", BRITISH JOURNAL OF HAEMATOLOGY, WILEY-BLACKWELL PUBLISHING LTD, GB LNKD- DOI:10.1111/J.1365-2141.1992.TB06940.X, vol. 82, 1 January 1992 (1992-01-01), pages 654 - 663, XP002138688, ISSN: 0007-1048 *
KOGAN T P: "THE SYNTHESIS OF SUBSTITUTED METHOXY-POLY(ETHYLENEGLYCOL) DERIVATIVES SUITABLE FOR SELECTIVE PROTEIN MODIFICATION", SYNTHETIC COMMUNICATIONS, TAYLOR & FRANCIS GROUP, PHILADELPHIA, PA LNKD- DOI:10.1080/00397919208019100, vol. 22, 1 January 1992 (1992-01-01), pages 2417 - 2424, XP000569631, ISSN: 0039-7911 *
LANG S ET AL: "Dual-targeted labeling of proteins using cysteine and selenomethionine residues", ANALYTICAL BIOCHEMISTRY, ACADEMIC PRESS INC, NEW YORK LNKD- DOI:10.1016/J.AB.2005.04.036, vol. 342, no. 2, 15 July 2005 (2005-07-15), pages 271 - 279, XP004972185, ISSN: 0003-2697 *

Also Published As

Publication number Publication date
US20110150820A1 (en) 2011-06-23
WO2010023670A2 (fr) 2010-03-04

Similar Documents

Publication Publication Date Title
WO2010023670A3 (fr) Procédés permettant de fixer par covalence un polymère à un résidu de méthionine dans des protéines et des peptides
IL282138A (en) A process for preparing purified drug compounds
UA91575C2 (ru) Дендример-пег с четырьмя ветвями для коньюгирования с белками и пептидами
WO2009100194A3 (fr) Conjugués à fraction de liaison à la camptothécine
WO2012012352A3 (fr) Peptides et protéines modifiés
WO2006134148A3 (fr) Conjugaison mediee par la transglutaminase d'une hormone de croissance
WO2012064733A3 (fr) Échafaudage d'anticorps pour conjugaison homogène
WO2007047303A3 (fr) Polypeptides glutenase peg
IL197498A (en) Hyaluronic Acid History Obtained Through a Cross-Link of "Tap Chemistry"
WO2007062037A3 (fr) Compositions et methodes de production de molecules hybrides de fixant a des antigenes, et leurs utilisations
IL192487A0 (en) Non-natural amino acid polypeptides having modulated immunogenicity
EP1981979A4 (fr) Procédé de production d'une forme native soluble de protéine recombinee utilisant la sequence signal et un agent renforçant la secretion
WO2009113828A3 (fr) Dérivés d'acides nucléiques peptidiques présentant une bonne pénétration cellulaire et une grande affinité pour les acides nucléiques
IL200113A0 (en) Chemical linkers with single amino acids and conjugates thereof
WO2007144709A3 (fr) DÉRIVÉS de LEPTOMYCINE
WO2007137114A3 (fr) Minichromosomes de plantes artificielles
WO2011146595A3 (fr) Réactifs zwitterioniques
HK1132752A1 (en) Novel antiproliferation antibodies
IL184690A0 (en) Process for producing polymer conjugates
EP1934252A4 (fr) Procedede synthese de conjugues d'insuline
EP2212020A4 (fr) Polymères imprimés présentant une affinité pour les protéines et les peptides phosphorylés
WO2007115724A3 (fr) Méthode destinée à augmenter le taux de récupération in vivo de polypeptides thérapeutiques
IL179303A0 (en) Preparation of macromolecular conjugates by four-component condensation reaction
WO2010014258A3 (fr) Conjugués possédant une liaison libérable
BRPI0520362A2 (pt) preparação de conjugados de insulina

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09743932

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 13060439

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09743932

Country of ref document: EP

Kind code of ref document: A2